Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

INVION LIMITED Director's Dealing 2019

Feb 17, 2019

65148_rns_2019-02-17_1e6fba65-f83f-4f91-9fbe-353e3e63eeb6.pdf

Director's Dealing

Open in viewer

Opens in your device viewer

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity INVION LIMITED ABN 76 094 730 417

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

We (the entity) give ASX the following
the director for the purposes of section
information under listing rule 3.19A.2 and as agent for
205G of the Corporations Act.
Name of Director DR GREG COLLIER
Date of last notice 19 March 2019

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest Change to indirect holdings.
Nature of indirect interest
(including registered holder)
Note: Provide details of the circumstances giving rise to the relevant
interest.
Indirect holdings are Beacon Super Fund Pty
Ltd ATF Beacon Super Fund of which Dr
Collier is a director and beneficiary; Barwon
Biotechnology Pty Ltd of which Dr Collier is
a director and shareholder; and Fusion
Biosciences Pty Ltd of which Dr Collier is a
director.
Date of change 12 February 2019
Total No. of securities held prior to change 23,437,599
fully
paid
ordinary
shares
(indirectly held).
Class Fully paid ordinary shares
Unlisted Share Options
  • See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Number acquired 8,333,333 Fully paid ordinary shares
136,288,073 Share options exercisable at
$0.03 each on or before 12 February 2023
(IVXAT).
Number disposed Nil.
Value/Consideration
Note: If consideration is non-cash, provide details and estimated
valuation
Nil Consideration. Share Options issued
following Shareholder Approval at EGM
held 30 January 2019.
Total No. of securities held after change 31,770,932
fully
paid
ordinary
shares
(indirectly held).
136,288,073 Share options exercisable at
$0.03 each on or before 12 February 2023
(IVXAT).
Nature of change
Example: on-market trade, off-market trade, exercise of options,
issue of securities under dividend reinvestment plan, participation in
buy-back
Share Options issued following Shareholder
Approval at EGM held 30 January 2019.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract n/a
Nature of interest n/a
Name of registered holder
(if issued securities)
n/a
Date of change n/a
No. and class of securities to which
interest related prior to change
Note: Details are only required for a contract in
relation to which the interest has changed
n/a
Interest acquired n/a
Interest disposed n/a
  • See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

Value/Consideration
Note: If consideration is non-cash, provide details
and an estimated valuation
n/a
Interest after change n/a

Part 3 –[+] Closed period

Part 3 –+Closed period
Were the interests in the securities or contracts detailed
above traded during a+closed period where prior written
clearance was required?
n/a
If so, was prior written clearance provided to allow the trade
to proceed during this period?
n/a
If prior written clearance was provided, on what date was this
provided?
n/a
  • See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 3